Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injectable NAD+ for Ovarian Function Decline (Phase II, China)
ChiCTR2600125759Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nicotinamide adenine dinucleotide in primary ovarian insufficiency (POI) (4 arms), sponsored by Peking University Third Hospital. Primary endpoints: Antral follicle count and Anti-Müllerian hormone. Planned start May 2026; status: not yet recruiting.
02
Drugs
nicotinamide adenine dinucleotide
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on ChiCTR2600125759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125759.